417 related articles for article (PubMed ID: 15262452)
1. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Seufert J; Lübben G; Dietrich K; Bates PC
Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review.
Natali A; Ferrannini E
Diabetologia; 2006 Mar; 49(3):434-41. PubMed ID: 16477438
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
Meriden T
Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
[TBL] [Abstract][Full Text] [Related]
5. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Chaudhuri A; Rosenstock J; DiGenio A; Meneghini L; Hollander P; McGill JB; Dandona P; Ilgenfritz J; Riddle M
Diabetes Metab Res Rev; 2012 Mar; 28(3):258-67. PubMed ID: 22081557
[TBL] [Abstract][Full Text] [Related]
6. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact.
Phielix E; Szendroedi J; Roden M
Trends Pharmacol Sci; 2011 Oct; 32(10):607-16. PubMed ID: 21824668
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
10. Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Stafford JM; Elasy T
Vasc Health Risk Manag; 2007; 3(4):503-10. PubMed ID: 17969380
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
[TBL] [Abstract][Full Text] [Related]
12. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of PPAR Gamma Agonism.
Campbell IW
Curr Mol Med; 2005 May; 5(3):349-63. PubMed ID: 15892654
[TBL] [Abstract][Full Text] [Related]
14. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
15. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
16. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients.
Susilawati E; Levita J; Susilawati Y; Sumiwi SA
Med Sci (Basel); 2023 Aug; 11(3):. PubMed ID: 37606429
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
19. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Satoh J
Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
[TBL] [Abstract][Full Text] [Related]
20. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
